One would think that a verdict of this magnitude would send a very loud, very clear message to Androgel maker AbbVie. Unfortunately, the testosterone therapy maker may actually escape paying on this verdict, calling into question whether the company will still “hear” the jury.
The $150 million testosterone verdict was just issued in the case of an Oregon man whose lawsuit accused AbbVie of hiding ...
continue reading...
As we’ve seen with the opioid epidemic sweeping across the country, the more available a prescription drug becomes, the greater the potential seems to become for that prescription drug to be abused. As drug companies flood American cities and towns with more painkillers than they could possibly take under normally-prescribed conditions, the number of overdoses and deaths has skyrocketed.
Sadly, that same kind of dependency and abuse is now starting to show ...
continue reading...The most recent report from the U.S. Judicial Panel on Multidistrict Litigation shows 2,231 testosterone lawsuits included in the Illinois MDL —and there’s no sign that the flood of lawsuits will let up any time soon. According to the Public Access to Court Electronic Records (PACER) database, over 40 new testosterone lawsuits were filed in the last week alone. A testosterone lawsuit filed last month by a ...
We recently posted an update detailing the 4.3% rise in AbbVie’s first-quarter profits. One year ago, the pharmaceutical giant posted profits of $980 million for the first three months of 2014. That, apparently, wasn’t enough. The first three months of 2015 saw profits of $1.02 billion for the Androgel manufacturer.
Profit is not a bad thing. Profit is how bills are paid, families are fed, and companies are ...
continue reading...Antares Pharma Incorporated saw dramatic falls in its stock price after hitting a roadblock in clinical trials of its prescription testosterone product. A patient developed an allergic reaction to the drug during the trial, causing the U.S. Food and Drug Administration (FDA) to request additional safety information. A Reuters’ article discusses the setback for the testosterone therapy manufacturer.
Concerns over the safety of prescription testosterone products have ...
continue reading...First Word Pharma reports that Androgel maker AbbVie has abandoned its plan to buy out pharmaceutical maker Shire. AbbVie says the bid for Shire was withdrawn in light of recent U.S. tax law changes. As a result of the failed deal, AbbVie will have to pay $1.6 billion to Shire and will be unable to make another offer to purchase the company for at least a year.
The Androgel maker was recently in the news over ...
continue reading...
